Isomorphic Labs, an AI-driven drug design company based in London, secured $600 million in its first external fundraising round led by Thrive Capital, with participation from GV (Google (NASDAQ:GOOGL) Ventures) and existing investor Alphabet. The company, which spun out from Alphabet’s DeepMind, focuses on using artificial intelligence to fundamentally redesign how drugs are discovered and developed. With new funding and strategic partnerships, Isomorphic Labs is moving to expand its technological capabilities and internal drug development programs, particularly in oncology and immunology. The company operates from its headquarters in London and also maintains an office in Lausanne, Switzerland.
Isomorphic Labs had previously been recognized for integrating DeepMind’s AlphaFold AI technology into its pipeline. AlphaFold’s earlier versions focused on protein folding prediction, but the unveiling of AlphaFold 3 in May 2024 expanded those capabilities to cover molecular structures and interactions. This model now forms a central part of Isomorphic’s AI drug design engine. The company’s alliance with Novartis, first announced in 2023 and deepened in 2025, has focused on applying AI to real-world therapeutic development, signaling a growing confidence among pharmaceutical firms in the reliability of AI-based systems.
How Will the Investment Be Used?
The newly secured capital will be directed toward enhancing Isomorphic Labs’ AI research and development initiatives. The company plans to advance its next-generation AI drug design engine and scale its operations by expanding staff across its offices. These steps are part of its broader strategy to transition from early-stage research to clinical development. In addition to internal projects, the company will continue collaborations with pharmaceutical partners to accelerate drug pipeline outputs.
What Are Stakeholders Saying?
“We’re excited to bring together a top-tier investor group with deep AI and life sciences expertise as we aim to transform this industry through an interdisciplinary approach,”
said Sir Demis Hassabis, founder and CEO of Isomorphic Labs. He added,
“This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI.”
“AI and machine learning have long held the promise of transforming drug discovery, yet few companies over the past decade have unlocked their full potential,”
said Dr. Krishna Yeshwant, Managing Partner at GV. He added,
“After witnessing the extraordinary pace of innovation at Isomorphic Labs, we believe their pioneering approach will redefine AI-powered drug discovery.”
“We believe Isomorphic has earned a rare position to define a new age of drug discovery and design, and we are deeply inspired by their mission and the extraordinary progress they have made to date,”
said Joshua Kushner, Founder and CEO of Thrive Capital.
While Isomorphic Labs’ previous milestones largely relied on internal research and the integration of AlphaFold into drug design, the new funding round signals a shift toward scalability and practical application in clinical programs. The involvement of major pharmaceutical companies and a broader investor base indicates growing industry acceptance of AI as an integral part of drug discovery. The announcement arrives at a time when both large pharmaceutical firms and AI-focused startups increasingly seek to bridge the gap between computational prediction and experimental validation, with Isomorphic positioning itself to play a central role in this convergence.
The application of AI technologies such as AlphaFold 3 in drug discovery reflects a broader trend of using computational models to predict biological interactions before clinical testing. This method could reduce the time and cost involved in identifying viable drug candidates. For readers following drug development trends, understanding how AI models are being integrated with pharmaceutical workflows provides insights into how companies may deliver treatments more efficiently. Stakeholders should also consider how collaboration between AI firms and traditional pharma is shaping the market and influencing regulatory approaches. As this space evolves, shifts in funding, regulation, and competitive positioning are likely to be key determinants of long-term success.
